|
Mr Guo said, to be honest, there are also special in Fosun dry unhappy place, that no matter how much you optimistic about the project, there is always a person has a veto, the man called Guo Guangchang.
The evening of June 10, the eve of the Shanghai International Film Festival, "Shanghai Fosun & Studio 8 Night" was held in the new world. Fosun chairman Guo Guangchang hand in Studio 8-founder and CEO Jeff Robinov, the famous director Ang Lee and other guests appeared, to the international capital elite from Hollywood, introduced Fosun "prosperous, healthy and happy" investment vision.
In the recent past, Fosun industry sector broke multiple internal personnel changes.
Die Zeit reporter found that one of the core industries Fosun Fosun plate (600196.SH, 02196.HK) also rise this year have left.
March 2, Fosun announcement, Upjohn Ling, senior vice president, Bing Li, vice president resigns; day, non-executive director Wang Pin-liang resigned due to job transfers. Followed by April 11, senior vice president of Fosun Li resign.
June 7, Yao Fang Fosun Pharma President and CEO resigns, replaced by Wu Yi-fang, vice president of Fosun took over; In addition, the same day the newly elected a director, and promoted three vice president to fill the executives leaving vacancies architecture brings.
"This year the company has been restructured management structure and business structure, and accordingly, managers at all levels are under adjustment and positioning functions." Fosun official said in response to an interview with Die Zeit reporter.
He specializes in mergers and acquisitions and investment Fosun Group, a large internal organs, many industrial sectors, many elite pool, which shares surging tide leaving the outside world has become the focus of attention.
In Fosun shareholders meeting held in Hong Kong recently, the investors referred to executives leaving the phenomenon of internal Fosun Group, Guo Guangchang which pointed out that "this is a bit like a siege, people want to come out, people inside I want to go out. Fosun use is the right person, not necessarily the best people. "
Executive personnel changes
June 7, 2015 Fosun Pharmaceutical Annual General Meeting held in Shanghai. On the temporary board of directors after the meeting, Fosun announced a major personnel changes, Fosun Pharma President and CEO Yao Fang resigned. Wu, vice president of Fosun aromatic successor as the new President and CEO for a term of three years, from June 7, 2016 until the expiry of the current term of the Board of Directors.
Die Zeit correspondent noted that the grounds on turnover Fosun Yao party, given is "because of work", but the whereabouts of the next job, not specifically explain, it remains as Fosun Executive Director, Deputy Director long positions.
Publication history shows that Yao party in April 2010 to join Fosun, namely the appointment of directors of the company after entry, is mainly responsible for the daily operations of the Group, reporting to the chairman Rudy Chan.
Yao party six years Fosun, Fosun health industry platform for rapid development of six years. Fosun first realized "A + H" shares listed on both, and then enter a number of cutting-edge field of medicine, to accelerate the internationalization of the industrial layout.
Yao Fang and Guo Guangchang Department alumni, graduated from Fudan University. Before joining Fosun, Yao has experienced a number of listed companies leaders in Shanghai pharmaceutical industry considerable prestige. In its almost as Fosun director while he was appointed as vice president of Shanghai Pharmaceutical Industry Association.
This coincided with the election of the Board Fosun, Fosun youngest "Marshal class" executives Wang Can, and Guo Guangchang, Wang Qunbin was elected as a non-executive director of Fosun.
Can Wang was born in 1979, close to "80", 2015, the Department Fosun one of the two new "70" executives.
Aged 37, he joined Fosun Wang Can in 2012, is now general manager of the Chief Financial Officer, the Board of Directors and President of the Office of Management and Investment Support Center Fosun Group, Fosun International (00656.HK) Chief Financial Officer. In early 2016, Fosun launch global partner system, Wang Cancheng Fosun 18 partners among the youngest.
Following the resignation of Yao Fang, Wang Can after taking office, on the day of the meeting, to be the most notable case of a new president and chief executive officer Wu Yi-fang, including 18 executives also be appointed.
Wu Yi-fang was born in 1969, close to "70", Rudy Chan older than 3 years old. Publication history shows that executives Wu Department of technical background 1987 - 1997, he was in Xuzhou Biochemical Pharmaceutical Factory (formerly a subsidiary of Fosun medicine IMC) veteran, served as technician, director, production chief, Treasurer, assistant director and other staff.
In 1996 this period, Wu Fang boss Rudy Chan served as deputy general manager of Fosun Pharmaceutical, that time the company has just listed, Chen became the youngest executives.
March 2007 to date, Wu Yi-fang Li Ren Wanbang Pharmaceutical president, chairman and CEO, in July 2014 has served as senior vice president of Fosun Pharma, and was promoted to chief operating officer earlier this year.
On the day of Fosun Board, Wu aryl by president nomination, agreed to appoint Wang Cheng (Chief Investment Officer), Hongfei Jia (and co-chief investment officer), off Scenic (Chief Financial Officer), Dong long, Song Jinsong Zhou Biao Chen Yuqing and senior vice president for the company.
By Wu aromatic nomination, appointment Cui Zhiping, Zhuyao Yi, Wang Kexin, Shao Ying, Mr Tung Chi-Chao, Wang Yao, Jing Ping Mei, Wang Donghua, Bonaventure Yong and Dong Xiaoxian (part-time secretary of the Board) as Vice President.
Die Zeit reporter found, said the newly appointed executives, a large number of people are "after 65", "70" and "80," which Wu Fang, Chen Yuqing, Bonaventure Yong and Dong Xiaoxian total of four people, all new Jin promoted.
"Our personnel is increasingly young, international, in the new board of directors and executive team can be seen, after '80 'has entered the management, young people will play a more significant role in the development of the company." Complex Star pharmaceutical official said in an interview.
Chen Yuqing is a "70", was born in December 1975, in January 2010 joined Fosun Pharmaceutical Department Rudy Chan, senior HR consultant, and served as vice president of human resources company, deputy general manager of human resources, general manager, president, assistant duties. April 2015, Chen Yuqing served as vice president of Fosun, and this appointment so that it ranks among the senior vice president of.
Another "70" executive Bonaventure Yong, aged 45, in May 2002 joined Fosun, the Department of technical background, sixth pharmaceutical factory in Chongqing (formerly Fosun Pharma's drug Chongqing Friends) started, dry over level technicians, field sales, sales director, etc., and in April 2014, he has been president of the Friends of the drug in Chongqing, vice chairman.
Is quite eye-catching, Fosun also a "80" executive vice president of Fosun, Deputy General Manager Dong Xiaoxian, the appointment of executives to become one of the youngest, she was born in March 1981, Fosun was added in 2003.
It is worth noting that Dong Xiaoxian has lasted nearly 10 years of work experience letter Phi. From July 2006 to June this year, he served as assistant Fosun securities, securities affairs representative, deputy director of the Office of the Deputy General Director positions.
Pharmaceutical Ecological test
Fosun International in 2015 Annual General Meeting June 1 held in Hong Kong on investor network Snowball announced the general meeting of shareholders to ask questions Fosun summary, faced with concerns of investors about Fosun brothers core team to leave, Guo Guangchang respond .
Mr Guo said, to be honest, there are also special in Fosun dry unhappy place, that no matter how much you optimistic about the project, there is always a person has a veto, the man called Guo Guangchang.
As for personnel changes Fosun made, the company official reply to Die Zeit reporter said, "the company's goal is to make more flat structure and integration to improve operational efficiency, enhance business collaboration."
Fosun Pharma is mainly engaged in pharmaceutical manufacturing and research and development, medical services, medical diagnostics and medical devices, pharmaceutical distribution and retail, in which pharmaceutical manufacturing and R & D oriented, and in health care services for the development focus.
Fosun existing in the territory, a total of five major business segments, namely, pharmaceutical manufacturing and research and development, medical services, medical diagnostics and medical device manufacturers / agents, as well as pharmaceutical distribution and retail.
Year 2015, operating income Fosun Pharmaceutical, pharmaceutical manufacturing and R & D operations to achieve revenues of 8.935 billion yuan, an increase of 21.78% compared with 2014; medical services business achieved revenues of 1.379 billion yuan, an increase of 16.26%; equipment agent revenues amounted to 529 million yuan, an increase of 21.48%.
It is understood that Fosun Pharma now has the management committee, the Management Committee pharmaceutical business and consumer, medical services management committee, as well as medical diagnostics division and Medical Devices division.
Drug manufacturing is the core business of Fosun Pharmaceutical, Wende Yong, vice president of the pharmaceutical industry and the current management committee deputy director. Friends of Chongqing medicine Yong Wende is located, has more than 70 years of development history. According to Chongqing Pharmaceutical Friends official website, its annual sales revenue of 20 billion yuan, net profit of nearly 200 million yuan, the main API products are sold to more than 75 percent of the United States and Europe and other markets.
Fosun pharmaceutical business in the territory, plays an important position. Dong long, senior vice president and chairman of Fosun Pharmaceutical Business and Consumer Commission.
Die Zeit reporter found, Dong long 2009 joined Fosun in the pharmaceutical business quite resources and background, current vice president of the China Association of Pharmaceutical Commerce, vice chairman of China Association of Pharmaceutical Commerce office.
In addition, senior vice president of medical services concurrently Song Jinsong Management Committee. Song is to join Fosun Group in July last year, after serving in the medical field has a rich history, he served in GE Healthcare's CT product manager, NMR Southern District Manager, Vice President and General Manager of Greater China and North China region HCS total manager and other staff.
In addition, by the vice president, chairman of Fosun medical diagnostics division Zhuyao Yi concurrently, he served as Beckman Coulter Trading (China) Co., Ltd. Manager.
The post of chairman and general manager Fosun Medical Devices division, respectively concurrently by Mr. HONGFEI JIA Yao Wang, senior vice president and vice president.
Fosun introduction, by providing the Commission and the Division is to promote the company's operating efficiency, continue to optimize management. In this trend, Fosun Pharma is seeking a broader development.
However, the current policy regime and environmental medicine is a growing adjustment, medical, pharmaceutical industry continued to break the ecological pattern, stringent regulatory unprecedented.
Especially since the end of last year, the State Food and Drug Administration (CFDA) issued the "history of the most stringent drug clinical trial data checking and order", cracked down hard on clinical trial data falsification.
CFDA's official website revealed that 82 pharmaceutical companies 131 drug applications withdrawn the registration, pharmaceutical companies and Shanghai Fosun Pharmaceutical (601607.SH), etc., have to withdraw the application for registration of drugs.
May 18 this year, a subsidiary of Fosun Pharma Food and Drug Administration department to withdraw agomelatine tablets, declared the production of an application for registration of sand Kubica song valsartan tablets and APIs. As of April 2016, Fosun on these two new drug R & D investment total of about 13.5 million yuan.
In addition, since March of this year, the pharmaceutical industry usher in consolidation, the medical device industry has ushered in an unprecedented large inventory.
June 7, CFDA issued "on the regulation of medical devices circulation management behavior of notice" (2016 No. 112), requires all Drug Administration System for medical devices circulation of illegal business conduct centralized major renovation.
The next day, CFDA also announced "to carry out clinical trials of medical devices supervision and inspection work notice", the medical device clinical trials also included in the regulatory system.
Fosun Pharma management team how to deal with the current complex domestic environment facing the pharmaceutical, wait and see the outside world.
|
Localhost:Home > Industry News >Detail
